Cover - shares |
3 Months Ended | |
|---|---|---|
Mar. 31, 2025 |
May 06, 2025 |
|
| Cover [Abstract] | ||
| Document Type | 10-Q/A | |
| Amendment Flag | true | |
| Amendment Description | This Amendment No 1. to the Quarterly Report on Form 10-Q of Immix Biopharma, Inc. (the “Company”) for the quarter ended March 31, 2025 (this “Amendment”) is being filed to amend the original Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed by the Company with the Commission on May 8, 2025 (the “Original Report”), to include certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, which were inadvertently omitted from the Original Report. These certificates are furnished, as Exhibit 32.1 to this Amendment.This Amendment contains only the Cover Page to this Amendment, this Explanatory Note, Item 6, the Signature Page, and the certifications attached to this Amendment as Exhibits 31.1 and 31.2 and Exhibit 32.1. No other changes have been made to the Original Form 10-Q. This Amendment speaks as of the original filing date of the Original Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the Original Form 10-Q. The filing of this Amendment is not an admission that the Original Form 10-Q, when filed, included any untrue statement of a material fact or omitted to state a material fact necessary to make a statement not misleading. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time of the Original Report. Accordingly, this Amendment should be read in conjunction with the Original Form 10-Q and our other filings with the SEC. | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Document Period End Date | Mar. 31, 2025 | |
| Document Fiscal Period Focus | Q1 | |
| Document Fiscal Year Focus | 2025 | |
| Current Fiscal Year End Date | --12-31 | |
| Entity File Number | 001-41159 | |
| Entity Registrant Name | IMMIX BIOPHARMA, INC. | |
| Entity Central Index Key | 0001873835 | |
| Entity Tax Identification Number | 45-4869378 | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Address, Address Line One | 11400 West Olympic Blvd. | |
| Entity Address, Address Line Two | Suite 200 | |
| Entity Address, City or Town | Los Angeles | |
| Entity Address, State or Province | CA | |
| Entity Address, Postal Zip Code | 90064 | |
| City Area Code | (310) | |
| Local Phone Number | 651-8041 | |
| Title of 12(b) Security | Common stock, $0.0001 par value | |
| Trading Symbol | IMMX | |
| Security Exchange Name | NASDAQ | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | true | |
| Elected Not To Use the Extended Transition Period | false | |
| Entity Shell Company | false | |
| Entity Common Stock, Shares Outstanding | 27,877,293 |